461 related articles for article (PubMed ID: 19359706)
1. Evaluation of dementia rating scales in Parkinson's disease dementia.
Harvey PD; Ferris SH; Cummings JL; Wesnes KA; Hsu C; Lane RM; Tekin S
Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):142-8. PubMed ID: 19359706
[TBL] [Abstract][Full Text] [Related]
2. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
3. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial.
Sevigny JJ; Peng Y; Liu L; Lines CR
Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):119-24. PubMed ID: 19949163
[TBL] [Abstract][Full Text] [Related]
4. The TE4D-Cog: a new test for detecting early dementia in English-speaking populations.
Mahoney R; Johnston K; Katona C; Maxmin K; Livingston G
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1172-9. PubMed ID: 16315149
[TBL] [Abstract][Full Text] [Related]
5. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.
Schmitt FA; Aarsland D; Brønnick KS; Meng X; Tekin S; Olin JT
Am J Alzheimers Dis Other Demen; 2010 Aug; 25(5):407-13. PubMed ID: 20392860
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
8. Cognitive dysfunctions in mild Parkinson's disease dementia: comparison with patients having mild Alzheimer's disease and normal controls.
Song IU; Kim JS; Yoo JY; Song HJ; Lee KS
Eur Neurol; 2008; 59(1-2):49-54. PubMed ID: 17917458
[TBL] [Abstract][Full Text] [Related]
9. Screening of mild cognitive impairment in Chinese older adults--a multistage validation of the Chinese abbreviated mild cognitive impairment test.
Lam LC; Tam CW; Lui VW; Chan WC; Chan SS; Chiu HF; Leung T; Tham MK; Ho KS; Chan WM
Neuroepidemiology; 2008; 30(1):6-12. PubMed ID: 18204291
[TBL] [Abstract][Full Text] [Related]
10. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale.
Pyo G; Elble RJ; Ala T; Markwell SJ
Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231
[TBL] [Abstract][Full Text] [Related]
11. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
12. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
13. Subjective memory complaints in Chinese subjects with mild cognitive impairment and early Alzheimer's disease.
Lam LC; Lui VW; Tam CW; Chiu HF
Int J Geriatr Psychiatry; 2005 Sep; 20(9):876-82. PubMed ID: 16116581
[TBL] [Abstract][Full Text] [Related]
14. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
[TBL] [Abstract][Full Text] [Related]
15. [Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono N; Mori E; Ikejiri Y; Imamura T; Shimomura T; Hashimoto M; Yamashita H; Ikeda M
No To Shinkei; 1997 Mar; 49(3):266-71. PubMed ID: 9125732
[TBL] [Abstract][Full Text] [Related]
16. The development and validation of a carer questionnaire to assess cognitive function in neuropsychiatric patients.
Randhawa S; Walterfang M; Miller K; Scholes A; Mocellin R; Velakoulis D
J Psychosom Res; 2007 Jul; 63(1):93-8. PubMed ID: 17586342
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Severe Impairment Battery for patients with Alzheimer's disease in Korea.
Suh GH; Kang CJ
Int J Geriatr Psychiatry; 2006 Jul; 21(7):626-32. PubMed ID: 16821258
[TBL] [Abstract][Full Text] [Related]
18. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
19. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
Kulisevsky J; Pagonabarraga J
Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
